摘要
自从第一个碳青霉烯(carbapenem)类抗生素被应用于临床,具有化学稳定、对肾脱氢肽酶稳定和改善体内动态的1β—甲基碳青霉烯的研究就广泛开展起来。比阿培南(biapenem)由日本 Lederle 公司研制并于2001年上市,经临床应用证明对各种细菌感染治疗效果优良,毒副反应少。
The study of 1βmethylcarbapenem was warming up extensively from the first an- tibiotic of arbapenem was used to clinic.Because it has the ability of chemical stability and the sta- bility to kidney dehydrogenase,and it can also improve the dynmic condition of our body.Beapen- em was developed by Lederle company of Japan,and was trown—into the market in 2001.Clinical application proves that the therapy result is good,and the toxic reaction or the side reaction is Iit- tle.
出处
《黑龙江医药》
CAS
2004年第6期444-446,共3页
Heilongjiang Medicine journal